Evotec SE has expanded a partnership with Celgene Corp to identify new treatments for neurodegenerative diseases using induced pluripotent stem (iPS) cells. This has triggering a milestone payment to the German company of $9 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
